UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported)
(Exact name of registrant as specified in its charter)
(State or other jurisdiction of incorporation) | (Commission File Number) | (I. R. S. Employer Identification No.) | ||||||||||||
(Address of principal executive offices, including ZIP code)
(800 ) 719-0671
(Registrant’s telephone number, including area code)
Not Applicable
(Former name or former address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
| Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) | |||||
| Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) | |||||
| Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) | |||||
| Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) | |||||
Securities registered pursuant to Section 12(b) of the Act:
| Title of each class | Trading Symbol(s) | Name of each exchange on which registered | ||||||||||||
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).
Emerging growth company ☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.
Item 2.02Results of Operations and Financial Condition.
On February 2, 2024, Twist Bioscience Corporation (the “Company”) issued a press release announcing its financial results for the quarter ended December 31, 2023. The full text of the press release issued in connection with the announcement is furnished as Exhibit 99.1 to this Current Report on Form 8-K.
The information furnished in this Item 2.02, including Exhibit 99.1, is being furnished and shall not be deemed to be “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that section, nor shall it be deemed to be incorporated by reference into any registration statement or other document filed pursuant to the Securities Act of 1933, as amended, except as shall be expressly set forth by specific reference in such filing.
Item 9.01Financial Statements and Exhibits.
(d)Exhibits.
| Exhibit No. | Description | |||||||
| 99.1 | ||||||||
| 104 | Cover Page Interactive Data File (formatted as Inline XBRL) | |||||||
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| Date: February 2, 2024 | Twist Bioscience Corporation | ||||
| /s/ Judy Yan | |||||
| Judy Yan | |||||
| Assistant General Counsel and Assistant Secretary | |||||
Exhibit 99.1
Twist Bioscience Reports Fiscal First Quarter 2024 Financial Results
– Record revenue of $71.5M in 1QFY24, an increase of 32% over $54.2M in 1QFY23 –
– Orders increased to $77.5M in 1QFY24, an increase of 19% over 1QFY23 –
— Increased FY 2024 revenue guidance to $288M to $293M; Increased FY 2024 gross margin guidance to 40% to 41% —
SOUTH SAN FRANCISCO, Calif. -- (February 2, 2024) — Twist Bioscience Corporation (NASDAQ: TWST), a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon platform, today reported financial results and business highlights for the first quarter of fiscal 2024 ended December 31, 2023.
"We're starting fiscal 2024 off strong with record revenue of $71.5 million for the first fiscal quarter, coming in above our projection, with a gross margin of 40.5%," said Emily M. Leproust, Ph.D., CEO and co-founder of Twist Bioscience. "In SynBio, after a limited launch of Express Genes in November, we expanded the offering to include midi and Maxi preps at Express speed and over time, we expect this offering will allow us to both expand our share of market and convert the Maker's Market of researchers who make their own genes into DNA buyers."
Dr. Leproust continued, "NGS had a strong quarter, with our top ten customers accounting for 44% of NGS revenue. As we move through the year, we plan to introduce new products and differentiated solutions to our customers and remain laser focused on revenue growth, margin expansion and financial discipline as we progress on our path to profitability."
FISCAL 2024 FIRST QUARTER FINANCIAL RESULTS
•Orders: Total orders received for the first quarter of fiscal 2024 increased to $77.5 million compared to $64.7 million for the same period of fiscal 2023.
•Revenue: Total revenues for the first quarter of fiscal 2024 increased to $71.5 million compared to $54.2 million for the same period of fiscal 2023.
◦Synbio revenue increased to $26.8 million for the first quarter of fiscal 2024 compared to $21.7 million for the same period of fiscal 2023.
▪Synthetic genes revenue increased to $19.7 million for the first quarter of fiscal 2024 compared to $16.2 million for the same period of fiscal 2023.
▪Oligo Pools revenue increased to $4.2 million for the first quarter of fiscal 2024 compared to $3.7 million for the same period of fiscal 2023.
▪DNA libraries revenue increased to $2.9 million for the first quarter of fiscal 2024 compared to $1.8 million for the same period of fiscal 2023.
◦NGS revenue increased to $39.4 million for the first quarter of fiscal 2024 compared to $24.4 million for the same period of fiscal 2023.
◦Biopharma revenue was $5.2 million for the first quarter of fiscal 2024 compared to $8.2 million in the same period of fiscal 2023.
•Cost of Revenues: Cost of revenues for the first quarter of fiscal 2024 was $42.5 million compared to $29.4 million for the same period of fiscal 2023.
•Research and Development Expenses: Research and development expenses for the first quarter of fiscal 2024 were $23.1 million compared to $31.2 million for the same period of fiscal 2023.
•Selling, General and Administrative Expenses: Selling, general and administrative expenses for the first quarter of fiscal 2024 were $52.8 million compared to $42.3 million for the same period of fiscal 2023.
•Net Loss: Net loss attributable to common stockholders for the first quarter of fiscal 2024 was $43.0 million, or $0.75 per share, compared to $41.8 million, or $0.74 per share, for the same period of fiscal 2023.
•Cash Position: As of December 31, 2023, the company had $311.1 million in cash, cash equivalents and short-term investments.
Recent Highlights:
•Shipped products to 2,140 customers in the first quarter of fiscal 2024, compared to approximately 2,060 customers in the first quarter of fiscal 2023.
•Shipped approximately 171,000 genes during the first quarter of fiscal 2024, compared with approximately 134,000 genes during the first quarter of fiscal 2023.
•On January 24, 2024, expanded Express Genes rapid gene synthesis service to all prep scales.
•Appointed Adam Laponis as chief financial officer.
Updated Fiscal 2024 Financial Guidance
The following statements are based on Twist’s current expectations for fiscal 2024, including the second quarter of fiscal 2024. The following statements are forward-looking, and actual results could differ materially depending on market conditions and the factors set forth under “Forward-Looking Statements” below.
For the full fiscal year 2024, Twist provided the following updated financial guidance:
•Total revenue is expected to be in the range of $288 million to $293 million, growth of 18 to 20 percent, and includes the following:
◦SynBio revenue is expected to be in the range of $114 million to $117 million compared to the previous estimate of $113 million to $116 million, indicating year over year growth of 16 to 19 percent
◦NGS revenue is expected to be in the range of $150 million to $152 million compared to the previous estimate of $147 million to $149 million, indicating year over year growth of 21 to 23 percent
◦Biopharma revenue is expected to be approximately $24 million compared to the previous estimate of approximately $25 million, indicating year over year growth of approximately 3 percent
•Gross margin is expected to be approximately 40% to 41% for fiscal 2024, an increase across the range
•Loss from operations before taxes of approximately $189 million to $194 million, an increase from $180 million to $188 million provided previously
◦Capital expenditure of $15 million, a decrease of $5 million from prior guidance
◦Ending cash, cash equivalents and short-term investments at September 30, 2024 of approximately $245 million, unchanged from previous guidance
For the second quarter of fiscal year 2024, Twist provided the following financial guidance:
•Total revenue of approximately $70 million to $71 million
◦SynBio revenue of approximately $28.5 million
◦NGS revenue of approximately $37 million to $38 million
◦Biopharma revenue of approximately $4.5 million
•Gross margin of 39%
Conference Call Information
The company plans to hold a conference call and live audio webcast for analysts and investors at 8:00 a.m. Eastern Time today to discuss its financial results and provide an update on the company’s business. The conference call will be webcast live through the Investor Relations section under the “Company” tab at www.twistbioscience.com. Those parties interested in participating via telephone must register on the Company’s Investor Relations website or by clicking here. Upon registration, all telephone participants will receive the dial-in number along with a unique PIN number that can be used to access the call. To avoid delays, we encourage participants to dial into the conference call fifteen minutes ahead of the scheduled start time. The webcast replay will be available for two weeks.
About Twist Bioscience
Twist Bioscience is a leading and rapidly growing synthetic biology and genomics company that has developed a disruptive DNA synthesis platform to industrialize the engineering of biology. The core of the platform is a proprietary technology that pioneers a new method of manufacturing synthetic DNA by “writing” DNA on a silicon chip. Twist is leveraging its unique technology to manufacture a broad range of synthetic DNA-based products, including synthetic genes, tools for next-generation sequencing (NGS) preparation, and antibody libraries for drug discovery and development. Twist is also pursuing longer-term opportunities in digital data storage in DNA and biologics drug discovery. Twist makes products for use across many industries including healthcare, industrial chemicals, agriculture and academic research.
Follow us on Twitter | Facebook | LinkedIn | YouTube | Instagram
Legal Notice Regarding Forward-Looking Statements
This press release contains forward-looking statements. All statements other than statements of historical facts contained herein are forward-looking statements reflecting the current beliefs and expectations of management made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995, including, but not limited to, projections under the heading “Updated Fiscal 2024 Financial Guidance” statements regarding future growth and expansion, timing of the development of data storage solutions, revenue growth, estimated annual revenues, ability and timing to achieve profitability and ability to increase gross margins and Twist Bioscience’s other expectations regarding its future operations plans and financial performance, introduction of new products, and newly announced partnerships. Forward-looking statements involve known and unknown risks, uncertainties, and other important factors that may cause Twist Bioscience’s actual results, performance, or achievements to be materially different from any future results, performance, or achievements expressed or implied by the forward-looking statements. Such risks and uncertainties include, among others, the ability to achieve the expected benefits of Twist Bioscience’s restructuring activities and reduced investments in DNA data storage; the ability to attract new customers and retain and grow sales from existing customers; the ability of Twist Bioscience to achieve sufficient revenue to achieve or maintain positive cash flow from operations or profitability in any given period; risks and uncertainties of rapidly changing technologies and extensive competition in synthetic biology that could make the products Twist Bioscience is developing obsolete or non-competitive; uncertainties of the retention of significant customers; the ability of Twist Bioscience to successfully integrate acquired companies and to achieve expected benefits from acquisitions; supply chain and other disruptions; risks of third party claims alleging infringement of patents and proprietary rights or seeking to invalidate Twist Bioscience’s patents or proprietary rights; and the risk that Twist Bioscience’s proprietary rights may be insufficient to protect its technologies. For a description of the risks and uncertainties that could cause actual results to differ from those expressed in these forward-looking statements, as well as risks relating to Twist Bioscience’s business in general, see Twist Bioscience’s risk factors set forth in Twist Bioscience’s Annual Report on Form 10-K filed with the Securities and Exchange Commission on November 21, 2023 and subsequent filings with the SEC. Any forward-looking statements contained in this press release speak only as of the date hereof, and Twist Bioscience specifically disclaims any obligation to update any forward-looking statement, whether as a result of new information, future events or otherwise.
For Investors:
Angela Bitting
SVP, Corporate Affairs
925-202-6211
abitting@twistbioscience.com
For Media:
Amanda Houlihan
Communications Manager
774-265-5334
ahoulihan@twistbioscience.com
Twist Bioscience Corporation
Condensed Consolidated Statements of Operations
(Unaudited)
(in thousands)
| Three months ended December 31, | ||||||||||||||
| (In thousands, except per share data) | 2023 | 2022 | ||||||||||||
| Revenues | $ | 71,498 | $ | 54,243 | ||||||||||
| Operating expenses: | ||||||||||||||
| Cost of revenues | $ | 42,536 | $ | 29,442 | ||||||||||
| Research and development | 23,099 | 31,242 | ||||||||||||
| Selling, general and administrative | 52,840 | 42,324 | ||||||||||||
| Change in fair value of contingent considerations and holdbacks | — | (4,135) | ||||||||||||
| Total operating expenses | $ | 118,475 | $ | 98,873 | ||||||||||
| Loss from operations | $ | (46,977) | $ | (44,630) | ||||||||||
| Interest income | 4,120 | 3,040 | ||||||||||||
| Interest expense | — | (1) | ||||||||||||
| Other income (expense), net | (31) | (157) | ||||||||||||
| Income tax (provision) / benefit | (120) | (76) | ||||||||||||
| Net loss attributable to common stockholders | $ | (43,008) | $ | (41,824) | ||||||||||
| Net loss per share attributable to common stockholders—basic and diluted | $ | (0.75) | $ | (0.74) | ||||||||||
| Weighted average shares used in computing net loss per share attributable to common stockholders—basic and diluted | 57,497 | 56,444 | ||||||||||||
Twist Bioscience Corporation
Condensed Consolidated Balance Sheets
(Unaudited)
(in thousands)
| (In thousands) | December 31, 2023 | September 30, 2023 | ||||||||||||
| Assets | ||||||||||||||
| Current assets: | ||||||||||||||
| Cash and cash equivalents | $ | 266,269 | $ | 286,470 | ||||||||||
| Short-term investments | 44,875 | 49,943 | ||||||||||||
| Accounts receivable, net | 35,354 | 44,064 | ||||||||||||
| Inventories | 30,863 | 32,063 | ||||||||||||
| Prepaid expenses and other current assets | 12,870 | 11,716 | ||||||||||||
| Total current assets | $ | 390,231 | $ | 424,256 | ||||||||||
| Property and equipment, net | 126,225 | 131,830 | ||||||||||||
| Operating lease right-of-use assets | 69,093 | 71,531 | ||||||||||||
| Other non-current assets | 147,266 | 148,786 | ||||||||||||
| Total assets | $ | 732,815 | $ | 776,403 | ||||||||||
| Liabilities and stockholders’ equity | ||||||||||||||
| Current liabilities: | ||||||||||||||
| Accounts payable | $ | 9,256 | $ | 14,052 | ||||||||||
| Accrued expenses | 13,959 | 10,754 | ||||||||||||
| Accrued compensation | 20,787 | 25,818 | ||||||||||||
| Current portion of operating lease liability | 14,808 | 14,896 | ||||||||||||
| Other current liabilities | 6,418 | 7,803 | ||||||||||||
| Total current liabilities | $ | 65,228 | $ | 73,323 | ||||||||||
| Operating lease liability, net of current portion | 77,070 | 79,173 | ||||||||||||
| Other non-current liabilities | 475 | 475 | ||||||||||||
| Total liabilities | $ | 142,773 | $ | 152,971 | ||||||||||
| Total stockholders’ equity | $ | 590,042 | $ | 623,432 | ||||||||||
| Total liabilities and stockholders’ equity | $ | 732,815 | $ | 776,403 | ||||||||||